A study for a 40 year old man who takes Rosuvastatin Zinc - from FDA reports


113 males aged 40 (±5) who take the same drug are studied. This is a personalized study for a 40 year old male patient who has High Cholesterol. The study is created by eHealthMe based on reports from FDA.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials).



On Sep, 14, 2018

113 males aged 40 (±5) who take Rosuvastatin Zinc are studied.


Number of reports submitted per year:

Rosuvastatin Zinc for a 40-year old man.

Information of the patient in this study:

  • Age: 40
  • Gender: male
  • Conditions: High Cholesterol
  • Drugs taken:
    • Rosuvastatin Zinc (rosuvastatin zinc)

eHealthMe real world results:

Comparison with this patient's adverse outcomes:

  • Muscular Weakness(muscle weakness): 0 (0% of males aged 40 (±5) who take the drug)

As an adverse outcome could be a symptom of a condition, additional studies are listed to help identify the cause: for example, regardless of which drug is taken, how many female HBP patients aged 50 (±5) have nausea

As an adverse outcome could be a side effect of a drug, additional studies are listed to help identify the cause: for example, how many female Aspirin users aged 50 (±5) have nausea

Most common side effects over time

< 1 month:
  1. Stable angina (a constant chest pain)
  2. Muscle aches (muscle pain)
  3. Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
1 - 6 months:
n/a
6 - 12 months:
n/a
1 - 2 years:
n/a
2 - 5 years:
n/a
5 - 10 years:
n/a
10+ years:
n/a
not specified:
  1. Weakness
  2. Eosinophilia (eosinophil count in the peripheral blood exceeds)
  3. Acute kidney failure
  4. Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
  5. High blood pressure

Top conditions involved for these people *:

  1. High Blood Pressure : 21 people, 18.58%
  2. Diabetes : 13 people, 11.50%
  3. Hiv Infection : 11 people, 9.73%
  4. Type 2 Diabetes : 11 people, 9.73%
  5. Pain : 10 people, 8.85%

Top co-used drugs for these people *:

  1. Metformin (24 people, 21.24%)
  2. Zolpidem (10 people, 8.85%)
  3. Darunavir (9 people, 7.96%)
  4. Sertraline (8 people, 7.08%)
  5. Lantus (8 people, 7.08%)

* Some reports may have incomplete information.

FDA reports used in this study

You are not alone:

What are the drugs?

What are the conditions?

What are the symtoms?

Could your drugs cause:

Could your conditions cause:



Related studies:

Related publications that referenced our studies

Recent updates

Recent general studies
Recent personal studies

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.